CARGO Therapeutics IncNASDAQ:CRGX
- LAST PRICE18.6800
- TODAY'S CHANGE (%)0.4000 (2.1882%)
- Bid / Lots7.4400/ 2
- Ask / Lots29.7400/ 2
- Open / Previous Close18.4600 / 18.2800
- Day Range
- 52 Week Range
- Volume89,542
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CRGX |
|---|---|---|
| 09:32 ET | 498 | 18.31 |
| 09:34 ET | 100 | 18.35 |
| 09:39 ET | 819 | 18.38 |
| 09:41 ET | 100 | 18.415 |
| 09:43 ET | 100 | 18.265 |
| 09:45 ET | 1976 | 18.495 |
| 09:50 ET | 100 | 18.62 |
| 09:52 ET | 100 | 18.74 |
| 10:03 ET | 100 | 18.71 |
| 10:06 ET | 100 | 18.79 |
| 10:19 ET | 1400 | 18.75 |
| 10:28 ET | 958 | 18.58 |
| 10:32 ET | 100 | 18.66 |
| 10:35 ET | 536 | 18.52 |
| 10:46 ET | 100 | 18.645 |
| 11:00 ET | 200 | 18.58 |
| 11:02 ET | 100 | 18.66 |
| 11:09 ET | 100 | 18.685 |
| 11:15 ET | 100 | 18.605 |
| 11:18 ET | 100 | 18.605 |
| 11:31 ET | 1000 | 18.5 |
| 11:36 ET | 1300 | 18.475 |
| 11:38 ET | 200 | 18.475 |
| 11:42 ET | 100 | 18.495 |
| 11:44 ET | 628 | 18.57 |
| 11:47 ET | 200 | 18.6 |
| 12:03 ET | 100 | 18.625 |
| 12:09 ET | 100 | 18.62 |
| 12:27 ET | 100 | 18.58 |
| 12:34 ET | 300 | 18.71 |
| 12:41 ET | 100 | 18.65 |
| 12:45 ET | 100 | 18.65 |
| 01:03 ET | 100 | 18.685 |
| 01:17 ET | 100 | 18.65 |
| 01:21 ET | 200 | 18.68 |
| 01:24 ET | 400 | 18.63 |
| 01:26 ET | 2118 | 18.78 |
| 01:28 ET | 100 | 18.81 |
| 01:51 ET | 300 | 18.84 |
| 01:53 ET | 100 | 18.795 |
| 02:00 ET | 200 | 18.81 |
| 02:08 ET | 300 | 18.75 |
| 02:11 ET | 100 | 18.685 |
| 02:13 ET | 300 | 18.715 |
| 02:31 ET | 100 | 18.62 |
| 02:42 ET | 300 | 18.62 |
| 02:47 ET | 1315 | 18.71 |
| 02:51 ET | 100 | 18.695 |
| 02:54 ET | 100 | 18.72 |
| 03:00 ET | 100 | 18.755 |
| 03:07 ET | 200 | 18.63 |
| 03:25 ET | 200 | 18.59 |
| 03:30 ET | 200 | 18.57 |
| 03:32 ET | 978 | 18.55 |
| 03:36 ET | 300 | 18.58 |
| 03:38 ET | 500 | 18.57 |
| 03:41 ET | 546 | 18.59 |
| 03:45 ET | 415 | 18.55 |
| 03:50 ET | 2498 | 18.57 |
| 03:52 ET | 1132 | 18.49 |
| 03:54 ET | 1197 | 18.5 |
| 03:56 ET | 1855 | 18.555 |
| 03:57 ET | 399 | 18.62 |
| 03:59 ET | 4208 | 18.68 |
Apr 15, 2024
CARGO Therapeutics Names Kapil Dhingra, M.B.B.S., to Board of Directors, from 4:05PM ET on Monday Apr 15, 2024 by Dow Jones
4:05PM ET on Monday Apr 15, 2024 by Dow JonesPress Release: CARGO Therapeutics Names Kapil Dhingra, M.B.B.S., to Board of Directors, from 4:05PM ET on Monday Apr 15, 2024 by Dow Jones
4:05PM ET on Monday Apr 15, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
CARGO Therapeutics Inc | 735.3M | -7.9x | --- |
Longboard Pharmaceuticals Inc | 710.5M | -8.2x | --- |
Zentalis Pharmaceuticals Inc | 784.8M | -2.4x | --- |
89Bio Inc | 786.6M | -4.1x | --- |
enGene Holdings Inc | 683.6M | -3.4x | --- |
Disc Medicine Inc | 680.0M | -7.9x | --- |
Company Information
CARGO Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in advancing curative cell therapies for cancer patients. Its programs, platform technologies, and manufacturing strategy are designed to directly address the chimeric antigen receptor (CAR) T-cell therapies. The CAR is a protein that has been engineered to modify T cells so they can recognize and destroy cancer cells. The Company’s lead program, firicabtagene autoleucel (CRG-022), is an autologous (derived from a patient’s cells) CD22 CAR T-cell product candidate. The Company is also engaged in evaluating CRG-022 in patients at earlier stages of disease, including large B-cell lymphoma (LBCL) and other hematologic malignancies. The Company is also leveraging its proprietary cell engineering platform technologies to develop a pipeline of programs that incorporate multiple transgene therapeutic designed by the Company to enhance CAR T-cell persistence and trafficking to tumor lesions.
Contact Information
- Headquarters
- 1900 Alameda De Las Pulgas, Suite 350SAN MATEO, CA, United States 94403
- Phone
- 650-379-6143
- Fax
- ---
Executives
- Independent Chairman of the Board
- John Orwin
- President, Chief Executive Officer, Director
- Gina Chapman
- Chief Financial Officer
- Anup Radhakrishnan
- Chief Technology Officer
- Shishir Gadam
- Chief Medical Officer
- Ginna Laport
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $735.3M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 39.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.37 |
Book Value | $9.84 |
P/E Ratio | -7.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
